PMID- 35660634
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220907
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 348
DP  - 2022 Aug
TI  - Preparation and application of pH-responsive drug delivery systems.
PG  - 206-238
LID - S0168-3659(22)00327-3 [pii]
LID - 10.1016/j.jconrel.2022.05.056 [doi]
AB  - Microenvironment-responsive drug delivery systems (DDSs) can achieve targeted 
      drug delivery, reduce drug side effects and improve drug efficacies. Among them, 
      pH-responsive DDSs have gained popularity since the pH in the diseased tissues 
      such as cancer, bacterial infection and inflammation differs from a physiological 
      pH of 7.4 and this difference could be harnessed for DDSs to release encapsulated 
      drugs specifically to these diseased tissues. A variety of synthetic approaches 
      have been developed to prepare pH-sensitive DDSs, including introduction of a 
      variety of pH-sensitive chemical bonds or protonated/deprotonated chemical 
      groups. A myriad of nano DDSs have been explored to be pH-responsive, including 
      liposomes, micelles, hydrogels, dendritic macromolecules and organic-inorganic 
      hybrid nanoparticles, and micron level microspheres. The prodrugs from 
      drug-loaded pH-sensitive nano DDSs have been applied in research on anticancer 
      therapy and diagnosis of cancer, inflammation, antibacterial infection, and 
      neurological diseases. We have systematically summarized synthesis strategies of 
      pH-stimulating DDSs, illustrated commonly used and recently developed 
      nanocarriers for these DDSs and covered their potential in different biomedical 
      applications, which may spark new ideas for the development and application of 
      pH-sensitive nano DDSs.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Ding, Haitao
AU  - Ding H
AD  - Department of Biotherapy, Department of Radiology, and Department of Urology, 
      Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for 
      Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu 610041, China.
FAU - Tan, Ping
AU  - Tan P
AD  - Department of Biotherapy, Department of Radiology, and Department of Urology, 
      Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for 
      Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu 610041, China.
FAU - Fu, Shiqin
AU  - Fu S
AD  - Department of Biotherapy, Department of Radiology, and Department of Urology, 
      Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for 
      Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu 610041, China.
FAU - Tian, Xiaohe
AU  - Tian X
AD  - Department of Biotherapy, Department of Radiology, and Department of Urology, 
      Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for 
      Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu 610041, China.
FAU - Zhang, Hu
AU  - Zhang H
AD  - Amgen Bioprocessing Centre, Keck Graduate Institute, CA 91711, USA.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Department of Biotherapy, Department of Radiology, and Department of Urology, 
      Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for 
      Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu 610041, China. Electronic address: 
      maxuelei0726@wchscu.cn.
FAU - Gu, Zhongwei
AU  - Gu Z
AD  - Department of Biotherapy, Department of Radiology, and Department of Urology, 
      Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for 
      Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu 610041, China.
FAU - Luo, Kui
AU  - Luo K
AD  - Department of Biotherapy, Department of Radiology, and Department of Urology, 
      Huaxi MR Research Center (HMRRC), Cancer Center, Frontiers Science Center for 
      Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu 610041, China; Functional and Molecular 
      Imaging Key Laboratory of Sichuan Province, and Research Unit of Psychoradiology, 
      Chinese Academy of Medical Sciences, Chengdu, 610041, China. Electronic address: 
      luokui@scu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220608
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Drug Carriers)
RN  - 0 (Micelles)
SB  - IM
MH  - Drug Carriers/chemistry
MH  - Drug Delivery Systems
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Inflammation/drug therapy
MH  - Micelles
MH  - *Nanoparticles/chemistry
MH  - *Neoplasms/drug therapy
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Controlled drug release
OT  - Drug delivery systems
OT  - Drug-loading/conjugate
OT  - Nanomedicine
OT  - pH-sensitive
EDAT- 2022/06/07 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/06/06 11:42
PHST- 2022/04/04 00:00 [received]
PHST- 2022/05/29 00:00 [revised]
PHST- 2022/05/30 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/06/06 11:42 [entrez]
AID - S0168-3659(22)00327-3 [pii]
AID - 10.1016/j.jconrel.2022.05.056 [doi]
PST - ppublish
SO  - J Control Release. 2022 Aug;348:206-238. doi: 10.1016/j.jconrel.2022.05.056. Epub 
      2022 Jun 8.